Northwire Canada EditionSunday, October 18, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
M&A / Property

Arch Biopartners Expands Phase II Cardiac Surgery-Associated AKI Trial to Include Royal Columbian Hospital in British Columbia

By The Northwire Desk — AI Analysis Nov 05, 2025 · 08:30 ARCH · 1.03 Arch Biopartners Inc.
ARCH · Price

Executive Summary

  • The Royal Columbian Hospital received REB approval to join Arch’s Phase II LSALT peptide trial for cardiac‑surgery associated acute kidney injury, becoming the eighth global site and fourth in Canada.
  • TSX Venture Exchange gave final approval for Arch’s acquisition of Lipdro Therapeutics Inc., issuing 250,000 Arch common shares plus a royalty on future CKD drug sales.
  • The Board granted 750,000 stock options to directors and officers at $1.70 per share, exercisable over ten years.

Key Details

  • Clinical Trial Expansion
  • REB approval obtained for Royal Columbian Hospital (RCH) in New Westminster, BC.
  • RCH will complete operational approvals, training, and site initiation before patient enrollment.
  • RCH is the eighth global site and expected to be the fourth Canadian recruiting location.

  • Other active sites: Toronto General Hospital (UHN), University of Calgary Cumming School of Medicine; St. Michael’s Hospital awaiting Clinical Trials Ontario authorization.

  • Acquisition of Lipdro Therapeutics

  • TSX Venture Exchange approved Arch’s acquisition of Lipdro Therapeutics Inc.
  • Consideration: 250,000 Arch common shares issued to Lipdro shareholders.

  • Additional consideration: royalty on future net sales of CKD drug candidates derived from the newly acquired CKD platform targeting IL‑32.

  • Equity Compensation

  • Board approved issuance of 750,000 stock options to directors and officers under Arch’s stock option plan.
  • Exercise price: $1.70 per share.
  • Term: ten years, effective November 4 2025, subject to regulatory approvals.

  • Purpose: remuneration for service periods ending April 1 2025 and April 1 2026.

  • Company Context

  • Arch Biopartners focuses on therapies for acute and chronic kidney disease.
  • Pipeline highlights: LSALT peptide (Phase II CS‑AKI), Cilastatin (Phase II toxin‑induced AKI), CKD therapeutics (preclinical).

Notable Quotes

No direct quotes were provided in the release.

Read the original news release →

More from Arch Biopartners Inc.

Jun 04, 2026 · 07:41

Arch Biopartners Advances Dual AKI Pipeline Amid Steady Cash Burn and Dilutive Financing

Technical Study May 22, 2026 · 06:50

Arch Biopartners Doses First Patient in Phase II AKI Trial Amidst Dilution Concerns

Other Apr 30, 2026 · 07:00

Arch Biopartners Clinical Execution Continues Amidst Severe Capital Erosion and Liquidity Concerns

Other Apr 02, 2026 · 05:45

Arch Biopartners Closes Non-Brokered Private Placement

Financings Mar 30, 2026 · 06:03

Arch Biopartners Closes $600K Lifeline as Stock Tests 52-Week Lows Amid Dilution and Trial Rollout

Financings Mar 24, 2026 · 09:13

Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial

Production / Operations